Thrombolytic therapy in acute myocardial infarction

Seminars in Thrombosis and Hemostasis

Volumn 22, Issue 1, 1996, Pages 15-26

  Huber, Kurt ^a   Maurer, Gerald ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

APSAC; Myocardial infarction; rt PA; Streptokinase; Thrombolytic therapy

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ANISTREPLASE; ARGATROBAN; HEPARIN; HIRUDIN; STREPTOKINASE;

ACUTE HEART INFARCTION; ALLERGY; ANAPHYLAXIS; BLEEDING; BLOOD CLOT LYSIS; HEART ARRHYTHMIA; HUMAN; HYPOTENSION; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

EID: 0029914343     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-998988     Document Type: Review

References (115)

1. DeWood MA, J Spores, R Notske, LT Mouser, R Burroughs, MS Golden, T Lang: Prevalence of total coronary inclusion during the early hours of transmural myocardial infarction. N Engl J Med 303:897-902, 1980.
2. Davis MJ, AC Thomas: Plaque fissuring: The cause of acute myocardial infarction, sudden ischemic death, and crescendo angina. Br Heart J 53:363-373, 1985.
3. Fuster V, L Badimon, JJ Badimon, JH Chesebro: The pathogenesis of coronary artery disease and the acute coronary syndromes (part I). N Engl J Med 326:242-250, 1992.
4. Fuster V, L Badimon, JJ Badimon, JH Chesebro: The pathogenesis of coronary artery disease and the acute coronary syndromes (part II). N Engl J Med 326:310-318, 1992.
5. Reimer KA, JE Lowe, MM Rasmussen, RB Jennings: The wave front phenomenon of ischemic cell death: I. Myocardial infarct size vs duration of coronary occlusion in dogs. Circulation 56:786-793, 1977.
6. Cannon CP, EM Antman, R Walls, E Braunwald: Time as an adjunctive agent to thrombolytic therapy. J Thromb Thrombolysis 1:27-34, 1994.
7. TIMI study group: The Thrombolysis in Myocardial Infarction (TIMI) Trial; Phase I findings. N Engl J Med 312:932-936, 1985.
8. Neuhaus K-L, U Tebbe, M Gottwick, MAJ Weber, W Feuerer, W Niederer, W Haerer, F Praetorius, K-D Grosser, W Huhmann, H-W Hoepp, G Alber, A Sheikhzadeh, B Schneider: Intravenous recombinant tissue plasminogen activator (rt-PA) and urokinase in acute myocardial infarction: Results of the German activator urokinase study (GAUS). J Am Coll Cardiol 12:581-587, 1988.
9. PRIMI Trial Study Group: Randomized double-blind trial of recombinant prourokinase against streptokinase in acute myocardial infarction. Lancet 1:863-868, 1989.
10. Weaver WD, JK Hartmann, J Anderson, J Sobdski, A Sasahara, PS Reddy for the Pro-UK Study Group: New recombinant glycosylated prourokinase for treatment of patients with acute myocardial infarction. J Am Coll Cardiol 24:1242-1248, 1994.
11. Chesebro JH, G Knatterud, R Roberts, J Borer, LS Cohen, J Dalen, HT Dodge, CK Francis, D Hillis, P Ludbrook, JE Markis, H Mueller, ER Passamani, ER Powers, AK Rao, T Robertson, A Ross, TJ Ryan, BE Sobel, J Willerson, DO Williams, BL Zaret, E Braunwald: Thrombolysis in myocardial infarction (TIMI) trial, phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation 76:142-145, 1987.
12. Neuhaus KL, W Feuerer, S Jeep-Tebbe, W Niederer, A Vogt, U Tebbe: Improved thrombolysis with a modified dose regimen of recombinant tissue plasminogen activator. J Am Coll Cardiol 14:1566-1569, 1989.
13. Purvis JA, AJ McNeill, RA Siddiqui, MJ Roberts, BM McClements, D McEneaney, NP Campbell, MM Khan, SW Webb, CM Wilson, AAJ Adgey: Efficacy of 100 mg of couble-bolus alteplase in achieving complete perfusion in the treatment of acute myocardial infarction. J Am Coll Cardiol 23:6-10, 1994.
14. GISSI-2: A factorial randomized trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 336:65-71, 1990.
15. The International Study Group: In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomized between alteplase and streptokinase with or without heparin. Lancet 336:71-75, 1990.
16. ISIS-3: A randomized comparison of streptokinase vs tissue plasminogen activator vs anistreplase and aspirin plus heparin vs aspirin alone among 41,299 cases of suspected myocardial infarction. Lancet 339:753-770, 1992.
17. Zagher D, MS Gotsman: Thrombolysis in the era of the randomized trials. Curr Opin Cardiol 10:372-380, 1995.
18. de Bono DP, ML Simoons, J Tijssen, AER Arnold, A Betriu, C Burgersdijk, L Lopez Bescos, E Mueller, M Pfisterer, F Van de Werf, F Zijlstra, M Verstraete for the European Cooperative Study Group: Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: Results of a randomised double blind European Cooperative Study Group trial. Br Heart J 67:122-128, 1992.
19. Hsia J, WP Hamilton, N Kleiman, R Roberts, BR Chaitman, AM Ross for the Heparin-Aspirin Reperfusion Trial (HART) Investigators: A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 323:1433-1437, 1990.
20. The GUSTO Investigators: An international randomized trial comparing thrombolytic strategies for acute myocardial infarction. N Engl J Med 329:673-682, 1993.
21. Anderson JL, SG Sorensen, FL Moreno, RA Hackworthy, KF Browne, HT Dale, for the TEAM-2 Study Investigators: Multicenter patency trial of intravenous anistreplase compared with streptokinase in acute myocardial infarction. Circulation 83: 126-140, 1991.
22. Anderson JL, LC Becker, SG Sorensen, LA Karagounis, KF Browne, PK Shah, DC Morris, DJ Fintel, HS Mueller, AM Ross, SM Hall, JC Askins, AJ Doorey, CL Grines, FL Moreno, VJ Marder for the TEAM-3 Investigators: Anistreplase versus alteplase in acute myocardial infarction: Comparative effects on left ventricular function, morbidity and 1-day coronary artery patency. J Am Coll Cardiol 20:753-766, 1992.
23. Cannon CP, CH McCabe, DJ Diver, S Herson, RM Grenne, PK Shah, RF Sequeira, F Leya, JM Kirshenbaum, RD Magorien, ST Palmeri, V Davis, CM Gibson, WK Poole, E Braunwald and the TIMI 4 Investigators: Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: Results of the thrombolysis in myocardial infarction (TIMI) 4 trial. J Am Coll Cardiol 24:1602-1610, 1994.
24. Califf RM, EJ Topol, RS Stack, SG Ellis, BS George, DJ Kereiakes, JK Samaha, SJ Worley, JL Anderson, L Harrelson-Woodlief, TC Wall, HR Phillips III, CW Abbottsmith, RJ Candela, WH Flanagan, AA Sasahara, SJ Mantell, KL Lee for the TAMI Study Group: Evaluation of combination thrombolytic therapy and timing of cardiac catheterization in acute myocardial infarction. Results of Thrombolysis and Angioplasty in Myocardial Infarction-Phase 5 Randomized Trial (TAMI-5). Circulation 83:1543-1556, 1991.
25. Grines CL, SE Nissen, DC Booth, JC Gurley, N Chelliah, R Wolf, J Blankenship, MC Branco, K Benett, AN DeMaria and the Kentucky Acute Myocardial Infarction Trial (KAMIT) Group: A prospective, randomized trial comparing combination half-dose tissue-type plasminogen activator and streptokinase with full-dose tissue-type plasminogen activator. Circulation 84:540-549, 1991.
26. Huber K: Die koronare Reokklusion - ein ungelöstes Problem der Thrombolysetherapie des akuten Herzinfarktes. Innere Med 48:316-323, 1993.
27. Badimon L, R Lassila, JJ Badimon, S Vallabhajosula, JH Chesebro, V Fuster: Residual thrombus is more thrombogenic than severely damaged vessel wall. Circulation 78 (Suppl II):II-119-II-123, 1988.
28. ISIS-2 Collaborative Group: Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 2:349-360, 1988.
29. Antiplatelet Trialists' Collaborators: Collaborative overview of randomized trials of antiplatelet therapy - II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. Br Med J 308:159-168, 1994.
30. Yasuda T, HK Gold, RC Leinbach: Lysis of plasminogen activator-resistant platelet-rich coronary artery thrombus with combined bolus injection of recombinant tissue-type plasminogen activator and antiplatelet GPIIb/IIIa antibody. J Am Coll Cardiol 16:1728-1735, 1990.
31. Kleiman NS, EM Ohman, RM Califf, BS George, D Kereiakes, FV Aguirre, H Weisman, T Schaible, EJ Topol: Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study. J Am Coll Cardiol 22:381-389, 1993.
32. O'Connor CM, R Meese, R Carney, J Smith, E Conn, J Burks, C Hartman, S Roark, N Shadoff, M Heard III, B Mittler, G Collins, F Navetta, J Leimberger, K Lee, R Califf for the DUCCS Group: A randomized trial of intravenous heparin in conjunction with anistreplase (anisolated plasminogen streptokinase activator complex) in acute myocardial infarction: The Duke University Clinical Cardiology Study (DUCCS) 1. J Am Coll Cardiol 23:11-18, 1994.
33. Bleich SD, TC Nichols, RR Schumacher, DH Cooke, DA Tate, SL Teichman: Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. Am J Cardiol 66:1412-1417, 1990.
34. Tebbe U, J Windeler, I Boesl, H Hoffmann, J Wojcik, M Ashmawy, ER Schwarz, P von Loewis of Menar, P Rosemeyer, G Hopkins, H Barth: Thrombolysis with recombinant unglycosylated single-chain urokinase-type plasminogen activator (saruplase) in acute myocardial infarction: Influence of heparin on early patency rate (LIMITS Study). J Am Coll Cardiol 26:365-373, 1995.
35. Weitz JI, M Hudoba, D Massel, J Maraganore: Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 86:385-391, 1990.
36. Bar-Shavit R, A Eldor, I Vlodavsky: Binding of thrombin to subendothelial extracellular matrix. Protection and expression of functional properties. J Clin Invest 84:1096-2004, 1989.
37. Hirsh J: Heparins. Fibrinolysis 9 (Suppl 1):66-68, 1995.
38. Talbot M: Biology of recombinant hirudin (CGP 39393): A new prospect in the treatment of thrombosis. Semin Thromb Hemostas 15:293-301, 1989.
39. Badimon L, A Merino, JJ Badimon, JH Chesebro, V Fuster: Hirudin and other thrombin inhibitors: Experimental results and potential clinical applications. Trends Cardiovasc Med 1:261-267, 1991.
40. Cannon CP, CH McCabe, TD Henry, MJ Schweiger, RS Gibson, HS Mueller, RC Becker, NS Kleiman, JM Haugland, JL Anderson, BL Sharaf, SJ Edwards, WJ Rogers, DO Williams, E Braunwald: A pilot trial of recombinant desulfato-hirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 5 Trial. J Am Coll Cardiol 23:993-1003, 1994.
41. Antmen EM for the TIMI 9A Investigators: Hirudin in acute myocardial infarction: Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial. Circulation 90:1624-1630, 1994.
42. Hennekens CH, CJ O'Donell, PM Ridker: Current and future perspectives on antithrombotic therapy of acute myocardial infarction. Eur Heart J 16 (Suppl D):2-9, 1995.
43. Molhoek GP, GJ Laarman, DJA Lok, M Luz, JH Kingma, AA van den Bos, AH Bosma, P den Heijer: Effects of recombinant hirudin (HBW 023) on early and late coronary patency in acute myocardial infarction patients treated with streptokinase (the HIT-SK Study). Eur Heart J 16 (Suppl):177 (abstract), 1995.
44. Lee LV for the TIMI 6 Investigators: Initial experience with hirudin and streptokinase in acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 6 Trial. Am J Cardiol 75:7-13, 1995.
45. de Bono D: Complications of thromholytic therapy. Fibrinolysis 9 (Suppl 1):78-80, 1995.
46. Simoons ML, AP Maggioni, G Knatterud: Individual risk assessment for intracranial haemorrhage during thrombolytic therapy. Lancet 342:1523-1527, 1993.
47. de Bono D, RS More: Prevention and management of bleeding complications after thrombolysis. Int J Cardiol 38:1-6, 1993.
48. Gemill JD, KJ Hogg, FG Dunn, AP Rae, WS Hillis: Pre-dosing antibody levels and efficacy of thrombolytic drugs containing streptokinase. Br Heart J 72:222-225, 1994.
49. Lew AS, P Laramee, B Cercek, PK Shah, W Ganz: The hypotensive effect of intravenous streptokinase in patients with myocardial infarction. Circulation 72:1321-1325, 1985.
50. Breithardt G, G Hindricks, M Block, M Borggrefe, T Budde: Reperfusion arrhythmias: A myth? Fibrinolysis 9 (Suppl 1):81-86, 1995.
51. Cragg DR, HZ Friedman JD Bonema: Outcome of patients with acute myocardial infarction who are ineligible for thrombolytic therapy. Ann Intern Med 115:173-177, 1991.
52. Grines CL, AN DeMaria: Optimal utilization of thrombolytic therapy for acute myocardial infarction: Concepts and controversies. J Am Coll Cardiol 16:223-231, 1990.
53. Gurwitz JH, RJ Goldberg, JM Gore: Coronary thrombolysis for the elderly? JAMA 265:1720-1723, 1991.
54. Freeman MR, A Langer, RF Wilson, CD Morgan, PW Armstrong: Thrombolysis in unstable angina: Randomized double-blind trial of t-PA and placebo. Circulation 85:150-157, 1992.
55. de Feyter PJ, PW Serruys: Percutaneous transluminal coronary angioplasty for unstable angina. In Topol EJ (Ed): Textbook of Interventional Cardiology. Saunders, Philadelphia, 1994, pp 274-291.
56. Schoebel F-C, M Leschke, D Stein, M Heins, K Pels, TW Jax, B-E Strauer: Chronic-intermittent urokinase therapy in refractory angina pectoris. Fibrinolysis 9 (Suppl 1):121-125, 1995.
57. Yusuf S, P Held, S McMahon: Routine medical management of acute myocardial infarction: Lessons from overviews of recent randomized controlled trials. Circulation 82 (Suppl II):II-117-II-134, 1990.
58. Becker RC: Late thrombolytic therapy: Mechanisms of benefit and potential risk among patients treated beyond 6 hours. Coronary Artery Dis 4:293-304, 1993.
59. LATE Study Group: Late assessment of thrombolytic efficacy (LATE) study with alteplase 6-24 hours after onset of acute myocardial infarction. Lancet 342:759-766, 1993.
60. Estudio Multicentro Estreptoquinasa Republicas de America del Sur Collaborative Group: Randomzied trial of late thrombolysis in patients with suspected acute myocardial infarction. Lancet 342:767-772, 1993.
61. Fibrinolytic Therapy Trialists' (FFT) Collaborative Group: Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients. Lancet 343:311-322, 1994.
62. Maynard C, R Althouse, M Olsufka, JL Ritchie, KB Davis, JW Kennedy: Early versus late hospital arrival for acute myocardial infarction in the Western Washington Thrombolytic Therapy Trials. Am J Cardiol 63:1296-1300, 1989.
63. Braunwald E: Optimizing thrombolytic therapy of acute myocardial infarction. Circulation 82:1510-1513, 1990.
64. Willerson JT, OH Frazier: Reducing mortality in patients with extensive myocardial infarction. N Engl J Med 325:1166-1168, 1991.
65. Topol EJ: Validation of the early open infarct vessel hypothesis. Am J Cardiol 72:40G-45G, 1993.
66. Braunwald E: The open-artery theory is alive and well - again. N Engl J Med 329:1650-1652, 1993.
67. Herlitz, J, M Hartford, M Blohm, M Risenfors, BW Karlsson, S Holmberg: Effect of a media campaign on delay times and ambulance use in suspected acute myocardial infarction. Am J Cardiol 64:90-93, 1989.
68. MacCallum AG, PJ Stafford, C Jones, R Vincent, C Perez-Avila, DA Chamberlain: Reduction in hospital time to thrombolytic therapy by audit of policy guidelines. Eur Heart J 11 (Suppl F): 48-52, 1990.
69. European Myocardial Infarction Project Group: Prehospital thrombolytic therapy in patients with suspected acute myocardial infarction. N Engl J Med 329:383-389, 1993.
70. Weaver WD, M Cerqueira, AP Hallstrom, PE Litwin, JS Martin, PJ Kudenchuk, M Eisenberg for the Myocardial Infarction Triage and intervention Project Group: Prehospital-initiated vs hospital-initiated thrombolytic therapy. The Myocardial Infarction Triage and Intervention Trial. JAMA 270:1211-1216, 1993.
71. Rawles J on behalf of the GREAT Group: Halving of mortality at I year by domiciliary thrombolysis in the Grampian Region Early Anistreplase Trial (GREAT). J Am Coll Cardiol 23:1-5, 1994.
72. Lincoff AM, EJ Topol: Trickle down thrombolysis. J Am Coll Cardiol 21:1396-1398, 1993.
73. Karagounis L, SG Sorenson, F Moreno, JL Anderson: Does thrombosis in myocardial infarction (TIMI) perfusion grade 2 represent a mostly patent artery or a mostly occluded artery? Enzymatic and electrocardiographic evidence from the TEAM-2 study. J Am Coll Cardiol 19:1-10, 1992.
74. Anderson JL, LA Karagounis, LC Becker, SG Sorenson, RL Menlove for the TEAM-3 Investigators: TIMI-Perfusion Grade 3 but not Grade 2 results in improved outcome after thrombolysis for myocardial infarction: Ventriculographic, enzymatic, and electrocardiographic evidence from the TEAM-3 study. Circulation 87:1829-1839, 1993.
75. Clemmensen P, EM Ohman, DC Sevilla, NB Wagner, PS Quigley, P Grande, GS Wagner: Importance of early and complete reperfusion to achieve myocardial salvage after thrombolysis in acute myocardial infarction. Am J Cardiol 70:1391-1396, 1992.
76. The GUSTO Angiographic Investigators: The effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function, and survival after myocardial infarction. N Engl J Med 329:1615-1622, 1993.
77. Kleiman NS, HD White, EM Ohman, AM Ross LH Woodlief, RM Califf, DRJ Holmes, E Bates, M Pfisterer, A Vahanian, EJ Topol for the GUSTO Investigators: Mortality within 24 hours of thrombolysis for myocardial infarction. Circulation 90:2658-2665, 1994.
78. Vogt A, R von Essen, U Tebbe, W Feuerer, K-F Appel, K-L Neuhaus: Impact of early perfusion status of the infarct-related artery on short-term mortality after thrombolysis for acute myocardial infarction: Retrospective analysis of four German multicenter studies. J Am Coll Cardiol 21:1391-1395, 1993.
79. Hearse DJ, L Maxwell, C Saldanha, JB Gavin: The myocardial vasculature during ischemia and reperfusion: A target for injury and protection. J Mol Cell Biol 25:759-800, 1993.
80. Ito H, T Tomooka, N Sakai, H Yu, Y Higashino, K Fujii, T Masuyama, A Kitabatake, T Minamino: Lack of myocardial perfusion immediately after successful thrombolysis. A predictor of poor recovery of left ventricular function in anterior myocardial infarction. Circulation 85:1699-1705, 1992.
81. O'Keefe JHJ, BD Rutherford, DR McConahay, WLJ Johnson, LV Giorgi, TM Shimshak, RW Ligon, BD McAllister, GO Hartzler: Myocardial salvage with direct coronary angioplasty for acute infarction. Am Heart J 123:1-6, 1992.
82. Eckmann MH, JB Wong, DN Salem, SG Pauker: Direct angioplasty for acute myocardial infarction. Am Heart J 117:667-676, 1992.
83. Grines CL, KF Browne, J Marco, D Rothbaum, GW Stone, J O'Keefe, P Overlie, B Donohue, N Chelliah, GC Timmis, RE Vliestra, M Strzelecki, S Puchrowivz-Ochocki, WW O'Neill: A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N Engl J Med 328:673-679, 1993.
84. Zijlstra F, MJ de Boer, JC Hoorntje, S Reiffers, JH Reiber, H Suryapranata: A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med 328:680-684, 1993.
85. Gibbons RJ, DR Holmes, GS Reeder, KR Bailey, MR Hopfenspirger, BJ Gersh: Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. N Engl J Med 328:685-691, 1993.
86. Goldman L: Cost and quality of life: Thrombolysis and primary angioplasty. J Am Coll Cardiol 25 (Suppl):38S-41S, 1995.
87. Michels KB, S Yusuf: Does PTCA in acute myocardial infarction affect mortality and reinfarction rates? A quantitative overview (meta-analysis) of the randomized clinical trials. Circulation 91: 476-485, 1995.
88. Lee L, ER Bates, B Pitt, JA Walton, N Laufer, WW O'Neill: Percutaneous transluminal coronary angioplasty improves survival in acute myocardial infarction complicated by cardiogenic shock. Circulation 78:1345-1351, 1988.
89. Topol EJ: Mechanical interventions for acute myocardial infarction. In: Topol EJ (Ed): Textbook for Interventional Cardiology, Saunders, Philadelphia, 1990, pp 269-299.
90. Rapaport E: Early versus late opening of coronary arteries: The effect of timing. Clin Cardiol 13 (Suppl 8):VIII 18-VIII 22, 1990.
91. Ruocco NAJ, BA Bergelson, AK Jacobs, MM Frederick, DP Faxon, TJ Ryan: Invasive versus conservative strategy after thrombolytic therapy for acute myocardial infarction with antecedent angina: A report from Thrombolysis in Myocardial Infarction Phase II (TIMI II). J Am Coll Cardiol 20:1445-1451, 1992.
92. Topol EJ, RM Califf, BS George, DJ Kereiakes, CW Abbott-smith, RJ Candela, KL Lee, B Pitt, RS Stack, WW O'Neill: A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med 317:581-588, 1987.
93. The TIMI Research Group: Immediate vs delayed catheterization and angioplasty following thrombolytic therapy for acute myocardial infarction. JAMA 260:2849-2858, 1988.
94. Simoons ML, AE Arnold, A Betriu, DP de Bono, J Col, FC Dougherty, R von Essen, H Lambertz, J Lubsen, B Meier: Thrombolysis with tissue plasminogen activator in acute myocardial infarction: No additional benefit from immediate PTCA. Lancet 1:197-203, 1988.
95. Arnold AE, ML Simoons, F Van de Werf, DP de Bono, J Lubsen, JG Tijssen, PW Seeruys, M Verstraete: Recombinant tissue-type plasminogen activator and immediate angioplasty in acute myocardial infarction: One year follow-up. Circulation 86:111-120, 1992.
96. International Society and Federation of Cardiology and World Health Organization Task Force on Myocardial Reperfusion: Reperfusion in acute myocardial infarction. Circulation 90:2091-2102, 1994.
97. Gulba DC, R Dechend, S Hauck, K-J Osterziel, M Barthels, PR Lichtlen, R Dietz: An accelerated "frontloaded" rt-PA thrombolysis regimen achieves higher TIMI III patency rates in acute myocardial infarction. Fibrinolysis 8 (Suppl 1): 100, 1994.
98. Collen D, JM Stassen, F De Cock: Synergistic effect on thrombolysis of sequential infusion of tissue-type plasminogen activator (t-PA) single-chain urokinase-type plasminogen activator (scuPA) and urokinase in the rabbit jugular vein thrombosis model. Thromb Haemostas 58:943-946, 1987.
99. Zarich SW, GJ Kowalchuk, WD Weaver, J Loscalzo, M Sassower, K Manzo, C Byrnes, JE Muller, V Gurewich for the PATENT Study Group: Sequential combination thrombolytic therapy for acute myocardial infarction: Results of the Prourokinase and t-PA Enhancement of Thrombolysis (PATENT) Trial. J Am Coll Cardiol 26:374-379, 1995.
100. Gulba D, M Barthels, M Westhoff-Bleck, S Jost, W Rafflenbeul, W Daniel, H Hecker, P Lichtlen: Increased thrombin levels during thrombolytic therapy in acute myocardial infarction. Relevance for the success of therapy. Circulation 83:937-944, 1991.
101. Montrucchio G, S Bergerone, F Bussolino, G Alloatti, L Silvestro, E Lupia, A Cravetto, M Di Leo, G Emanuelli, G Camussi: Streptokinase induces intravascular release of platelet-activating factor in patients with acute myocardial infarction and stimulates its synthesis by cultured human endothelial cells. Circulation 88: 1476-1483, 1993.
102. Smalling RW, C Bode, J Kalbfleisch, S Sen, P Limbourg, F Forycki, G Habib, R Feldman, S Hohnloser, A Seals and the RAPID Investigators: More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. Circulation 91:2725-2732, 1995.
103. Bode C, RW Smalling, J Kalbfleisch, G Berg, DJ Odenheimer, E Böhm, WD Weaver and the RAPID II Investigators: Randomized comparison of double bolus reteplase (t-PA) and front-loaded alteplase (rt-PA) in patients with acute myocardial infarction (RAPID II). Eur Heart J 16 (Suppl):11, 1995.
104. Hampton J, W Meyer-Sabellek, R Schröder, R Wilcox and the INJECT Trial Study Group: International Joint Efficacy Comparison of Thrombolytics (INJECT): Reteplase vs Streptokinase in acute myocardial infarction. J Am Coll Cardiol 26 (Suppl):87A, 1995.
105. Collen D, J-M Stassen, T Yasuda, C Refino, N Paoni, B Keyt, T Roskams, JL Guerrero, HR Lijnen, HK Gold, WF Bennett: Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog. Thromb Haemostas 72:98-104, 1994.
106. Keyt B, NF Paoni, CJ Refino, L Berleau, H Nguyen, A Chow, J Lai, L Pena, C Pater, J Ogez, T Etcheverry, D Botstein, WF Bennett: A faster acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci USA 91:3670-3674, 1994.
107. Huber K, R Beckmann, F Rauscha, P Probst, F Kaindl, BR Binder: The role of type-1 plasminogen activator inhibitor in failure of thrombolytic therapy with recombinant tissue plasminogen activator. Z Kardiol 82 (Suppl 1):194-199, 1993.
108. Vanderschueren SMF, HR Lijnen, D Collen: Properties of staphylokinase and its potential as a thrombolytic agent. Fibrinolysis 9 (Suppl 1):87-90, 1995.
109. Collen D, F Van de Werf: Coronary thrombolysis with recombinant staphylokinase in patients in the evolving myocardial infarction. Circulation 87:1850-1853, 1993.
110. Gulba DC, M Praus, W Witt: DSPA alpha-properties of the plasminogen activators of the vampire bat Desmodus rotundus. Fibrinolysis 9 (Suppl 1):91-96, 1995.
111. Witt W, B Maass, B Baldus, M Hildebrand, P Donner, W-D Schleunig: Coronary thrombolysis with Desmodus salivary plasminogen activator in dogs - fast and persistent recanalization by intravnous bolus administration. Circulation 90:421-426, 1994.
112. Haber E: New fibrinolytic agents - future developments. Fibrinolysis 9 (Suppl 1):100-103, 1995.
113. Bode C, M Hudelmayer, P Mehwald, S Bauer, M Freitag, E von Hodenberg, JB Newell, W Kübler, E Haber, MS Runge: Fibrintargeted recombinant hirudin inhibits fibrin deposition on experimental clots more efficiently than recombinant hirudin. Circulation 90:1956-1963, 1994.
114. Vaughan DE, PJ Declerck, E Van Houtte, M De Mol, D Collen: Reactivated recombinant plasminogen activator inhibitor-I (rPAI-1) effectively prevents thrombolysis in vivo. Thromb Haemostas 68:60-63, 1992.
115. Levi M, BJ Biemond, AJ van Zonneveld, JW ten Cate, H Pannekoek: Inhibition of plasminogen activator inhibitor-I activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis. Circulation 85:305-312, 1992.